Please assess the completion status of the following clinical trial:

Trial Title: Aminophylline and Cognitive Function After Sevoflurane Anaesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA I-II patients~2. aged 18-55 years~3. scheduled for elective ambulatory surgery~4. duration \>1 h under general anaesthesia~Exclusion Criteria:~1. cardiovascular diseases~2. respiratory diseases~3. neurological diseases~4. psychiatric diseases~5. pregnancy~6. obesity~7. adverse reaction to aminophylline or sevoflurane~8. receiving xanthines, ß-agonist, anticholinergic~9. history of cognitive dysfunction~10. cerebrovascular disease~11. recent history of infection or recent fever~12. adverse reaction to aminophylline or sevoflurane~13. alcoholism~14. drug dependence~15. those receiving xanthines, ß-agonist, anticholinergic, tranquilizers, anticonvulsants or antidepressants~16. those who has habitual coffee consumption exceeding 2 cups per day~17. unable to read~18. suffering from serious hearing or vision impairment~19. those who had not completed primary school

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo [group P] (Type: PLACEBO_COMPARATOR): None
- Aminophylline 2 mg/Kg [group A2] (Type: ACTIVE_COMPARATOR): None
- Aminophylline 3 mg/Kg [group A3] (Type: ACTIVE_COMPARATOR): None
- Aminophylline 4mg/Kg [group A4] (Type: ACTIVE_COMPARATOR): None
- Aminophylline 5 mg/Kg [group A5] (Type: ACTIVE_COMPARATOR): None
- Doxapram 1 mg/kg [group D] (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).